Sato Y, Nunoi K, Kaku K, Yoshida A, et al. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. Diabetes Obes Metab 2020;22:222-230.
PMID: 31608549